Skip to main content
Equibles
NMRA logo

NMRA · Neumora Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track NMRA — free

Use NMRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.50 +0.00 (+0.02%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$127.32M
Shares
187.90M
Volume · Oct 5 1.24M Avg daily vol (3M) 1.14M

Neumora Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Neumora Therapeutics, Inc. (NMRA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-04-13
Neumora Therapeutics, Inc. (NMRA) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-30
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Confident tone NMRA-215 obesity program and rat tox findings NMRA-511 in Alzheimer's disease agitation M4 PAM franchise / NMRA-898 in schizophrenia
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-06
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Confident tone Obesity / NMRA-215 NLRP3 inhibitor lead indication M4 PAM franchise (NMRA-861, NMRA-898) Navacaprant KOASTAL Phase III in MDD
Diluted EPS
$-0.33
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Positive tone KOASTAL Phase 3 program (navacaprant in MDD) KOASTAL-1 failure and study modifications NMRA-511 in Alzheimer's disease agitation
Diluted EPS
$-0.42
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Positive tone Navacaprant (KOASTAL Phase 3 program in MDD) Regulatory engagement and trial design Leadership transitions
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Confident tone Navacaprant / KOASTAL Phase 3 program in MDD Pipeline breadth and additional programs Clinical validation and safety profile
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Showing 1–6 of 6 webcasts
Key facts CIK 1885522 CUSIP 640979100 13F (30d) 2 filings 2 filers Visit website Investor relations